New Published Paper Shows Efficacy Of Lpath, Inc.'s Anti-LPA Antibody, Lpathomab, In Traumatic Brain Injury Models
3/5/2014 10:37:34 AM
More...
|
Lpath, Inc. To Present At Upcoming ROTH Investor Conference
3/4/2014 6:53:19 AM
More...
|
Lpath, Inc. Granted Key U.S. Patent Related To Ocular Drug Program, iSONEP
1/23/2014 10:48:47 AM
More...
|
Lpath, Inc. Provides Update on Plans for iSONEP Option
10/9/2013 9:00:53 AM
More...
|
Lpath, Inc. Awarded National Institutes of Health (NIH) SBIR Grant for Lpathomab
9/23/2013 9:56:06 AM
More...
|
Lpath, Inc. to Present at the 2013 JMP Healthcare Conference on July 9
7/3/2013 11:30:51 AM
More...
|
Lpath, Inc. Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
5/30/2013 9:18:04 AM
More...
|
Lpath, Inc. Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
5/23/2013 9:40:05 AM
More...
|
Lpath, Inc. Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP
3/22/2013 9:00:37 AM
More...
|
Lpath, Inc. to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013
3/12/2013 9:13:49 AM
More...
|
|